Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739326 | 0.75 | SMN1; SMN2 (0.60) | HPGDMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL13753571 | 0.74 | HPGD (0.49) | GAAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL13740440 | 0.73 | SMN1; SMN2 (0.63) | HPGDMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL1041466 | 0.72 | NOTUM (0.53) | MEN1KMT2AALDH1A1 | |
| SCHEMBL10371971 | 0.72 | MAPT (0.42) | GAAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL2930813 | 0.71 | L3MBTL1 (0.44) | GAAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL24163381 | 0.69 | L3MBTL3 (0.57) | GAAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL12926042 | 0.69 | NR2E1 (0.59) | GAAHPGDALDH1A1POLBTSHR | |
| SCHEMBL15229957 | 0.68 | GAA (0.50) | GAAHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL13687490 | 0.68 | L3MBTL1 (0.39) | GAAMEN1KMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369474-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369474-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016090313-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369474-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | GAA 322/4885HPGD 3099/4885MEN1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.